Pancreatic ductal adenocarcinoma has a five-year survival rate of roughly 13 percent, according to the American Cancer ...

Pancreatic cancer has long been oncology’s most stubborn adversary. Fewer than 13% of patients survive five years after ...

UH engineers helped develop an mRNA-based strategy that boosts cancer-fighting T cells and, in mouse studies, helped ...

Ongoing federal support for mRNA technology and research could make good on a longstanding presidential promise to cure cancer, according to Jeff Coller, Bloomberg Distinguished Professor of RNA ...

Engineers from the University of Houston, MIT and Harvard have developed a new mRNA-based strategy that dramatically amplifies the T-cell response to vaccines - an advance that could lead to far more ...

A University of Florida research team led by Elias Sayour, M.D., Ph.D., (center) developed an mRNA vaccine that boosted the tumor-fighting effects of immunotherapy in a mouse-model study. Provided by ...

Add Yahoo as a preferred source to see more of our stories on Google. Personalized mRNA vaccines show promise as pancreatic cancer treatment, a phase 1 clinical trial published Wednesday in Nature ...

Pancreatic cancer remains one of the most difficult cancers to treat, with many patients facing a high risk of recurrence even after surgery and chemotherapy. Researchers are now exploring ...

The rapid clinical validation of mRNA technology during the COVID‑19 pandemic has powerfully accelerated its application in ...

Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "mRNA Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for mRNA Therapeutics ...